MARIN

534 Rec'

09/622719 T/PTO 22 AUG 2000

PROCESS FOR THE TREATMENT OF DISEASES OR DISORDERS OF THE INNER EAR

## DESCRIPTION

The invention firstly relates to a process for the treatment of diseases or disorders of the inner ear, which are linked with damage or destruction of the sensory cells of the inner ear.

The inner ear of humans and other mammals can either be irreversibly damaged from the outset by a genetic defect or subsequently by external influences. These external influences can e.g. be acoustic trauma or toxic or hypoxic influences. Such damage can lead to functional disturbances or losses of the senses located in the inner ear, particularly hearing. In the case of these functional disturbances particular reference must be made to a reduction or disappearance of the power of hearing. It is estimated that in Germany approximately 12 million people suffer from a so-called perceptive deafness, which can be attributed to the aforementioned pathogenetic mechanisms. Apart from the degeneration of sensory neurons and damage to the so-called stria vascularis of the inner ear, a cause of partial or complete loss of the power of hearing can in particular be damage or destruction of the sensory cells of the inner ear and consequently the hearing organ.

In a process for the treatment of diseases or disorders of the inner ear linked with damage or destruction of the sensory cells, it must be borne in mind that it is no longer possible to regenerate irreversibly damaged and therefore lost cells in the highly differentiated sensory epithelia in the inner ear of humans and other mammals. Thus, a partial or complete hearing loss due to damage or destruction of the sensory cells of the inner ear is generally irreversible. In this respect the sensory epithelia of the inner ear fundamentally differ from other tissues, where necrotic cells can be rapidly replaced by the division of substitute cells and their subsequent maturation.

It is of interest that in other vertebrate classes, such as e.g. birds, necrotic sensory cells in the inner ear can be regenerated, unlike the situation with humans. In birds sensory cells which have died after damage are replaced by so-called supporting cells located in the epithelium below the sensory cells. This takes place by division of the supporting cells and subsequent maturation, a new supporting cell and a sensory cell resulting from a supporting cell.

The discovery of the regeneration of sensory cells in the cochlea of the bird has over the past few years led to an attempt being made to transfer research results made on the bird to mammals and therefore ultimately humans. This inter alia promised success, because the cochlea of the bird and the cochlea

·自己等于1000年1月1日发展

10 1 6

of mammals have cell-biological points in common. Both the sensory epithelium of bird cochlea and the sensor epithelium of mammal cochlea are postmitotic, i.e. sensory cells present in the sensory epithelia are formed only during a specific time period of embryonic development, after which normally no further cell divisions occur. However, this fundamental point in common makes it difficult to understand the phenomenon that in the vestibular sensory epithelium of the bird cell divisions can be detected throughout its life, but not in humans.

As it was recognized in the bird that so-called growth factors can give rise to an increased proliferation rate in the bird cochlea, such growth factors were also used in the mammal cochlea. However, it was not possible to prove a reproducible action. This makes it obvious to draw the conclusion that despite fundamental cell-biological points in common, there must be other significant differences between bird and mammal cochlea. These could be that the supporting cells of the bird cochlea, as in the mammal, are postmitotic, but have only temporarily left the cell cycle. They can then reenter the cell cycle when a corresponding signal appears. Such supporting cells can be called quiescent, i.e. they are in the waiting state. As opposed to this the supporting cells of the mammal pass through a very high and specific differentiation and consequently irreversibly leave the cell cycle. They can consequently be called terminally differentiated and are e.g. comparable with neurons. This can apply in the case of the supporting cells of the mammal, which are referred to as so-called Pillar's or Deiter's cells. Such explanation models for cell-biological differences between bird and mammal cochlea have given rise to a more detailed investigation of the regeneration of the sensory cells in the bird in order to subsequently transfer the results obtained to mammals.

However, the problem of the present invention is to find a new starting point for the treatment of disorders or diseases of the inner ear, which are linked with damage or destruction of the sensory cells of the inner ear. The aim is less to transfer to mammals and in particular humans results obtained on vertebrates other than mammals and more to make available an action mechanism and corresponding active ingredients, which act directly in the cellular processes in the mammal and ultimately lead to a regeneration of the sensory cells of the inner ear.

This problem is solved by the process having the features of claim 1 and the process with the features of claims 2 and 3. Preferred developments are described in the dependent claims 4 to 21. Thus, by reference, the content of all the claims is made into part of the present description.

According to the invention, the process of the aforementioned type is

characterized in that at least one so-called cell cycle inhibitor present in the inner ear has its inhibiting action partly inhibited or eliminated by at least one active ingredient, which results in a regeneration of the sensory cells of the inner ear. From the patent law sense this process also incorporates the use of an active ingredient able to inhibit or eliminate the action of a cell cycle inhibitor present in the inner ear, either directly for the treatment of diseases or disorders of the inner ear or indirectly for preparing a pharmaceutical composition or a medicament for the treatment of diseases or disorders of the inner ear, said diseases/disorders being linked with damage or destruction of the sensory cells of the inner ear.

The regeneration of the sensory cells of the inner ear resulting from the process according to the invention preferably takes place through a stimulation of the proliferation of the supporting cells of the inner ear, i.e. the supporting cells also present in the sensory epithelium and usually located between and below the sensory cells. As there are one or more cell cycle inhibitors in the supporting cells of the inner ear, by inhibiting or eliminating their inhibiting action by a suitable active ingredient it is possible to initiate the cell division of the supporting cells, thereby creating a fundamental prerequisite for creating replacement or substitute cells for the necrotic or dead sensory cells. The cells resulting from the division of the supporting cells can then at least partly mature to functional sensory cells.

With regards to the sensory cells of the inner ear referred to up to now, these are preferably so-called hair sensory cells or short hair cells, which have at their upper end hair-like extensions, so-called stereocilia or small sensory hairs. These hair cells are located on the basilar membrane in the so-called corti-organ and form as so-called outer and inner hair cells the actual receptor cells for acoustic transduction in the inner ear. Both the inner and the outer hair cells are of interest for regeneration, regeneration of the outer hair cells representing a particular field of use of the invention as a result of their greater sensitivity. Those supporting cells which are anatomically particularly well associated with the inner or outer hair sensory cells can in particular be used for the active ingredient employed according to the invention. Thus, apart from outer hair sensory cells as supporting cells can be used the so-called Hensen's cells and, below the outer hair sensory cells, the so-called Deiter's cells and "outer" Pillar's cells. These Hensen's, Deiter's and outer Pillar's cells are consequently particularly suitable as replacement cells for the outer hair sensory cells. Correspondingly alongside and below the inner hair sensory cells are provided the so-called inner sulcus cells as supporting cells and within the inner hair sensory cells also the inner Pillar's cells, both being usable as replacement cells for the inner hair sensory cells. Thus, optionally a regeneration of inner or outer hair cells can be selectively initiated

1000年

and influenced. Reference can be made in this connection to the relevant textbooks and articles concerning the hearing process in mammals, particularly humans. The regeneration of the hair sensory cells participating in acoustic transduction in the inner ear for the treatment of perceptive deafness in the case of damage to said sensory cells represents the main field of use of the present invention.

The cell cycle inhibitors, whose inhibiting action is to be inhibited or eliminated according to the invention, can fundamentally be different physiological substances, particularly proteins, preventing the cell passing through the normal cell cycle, including cell division. They are preferably so-called cyclin-dependent kinase inhibitors (CDKIs). It is known that during the development of an organism they are expressed to a reinforced extent during the occurrence of terminally differentiated cells and in this way prevent the reentry of the cell into the cell cycle. This would also explain the loss of the dividability of such cells with reinforced expression of cyclin-dependent kinase inhibitors. Cell cycle inhibitors and in particular cyclin-dependent kinase inhibitors of the so-called CIP/KIP family can be selectively expressed in specific cell types. Preferred cyclin-dependent kinase inhibitors are in particular the proteins referred to as p21Cip1, p27Kip1 and p57Kip2. According to the invention preference is given to the cyclin-dependent kinase inhibitor p27Kip1. As a result of the selective expression of such inhibitors and the different expression patterns resulting therefrom, the invention can be used for selectively influencing the cell cycle in a specific cell type. If e.g. in a specific cell type, such as e.g. the supporting cells in the sensory epithelium of the inner ear, p27Kip1 is expressed selectively or at least with a significant proportion, by means of an active ingredient aimed specifically at this inhibitor, it is possible to eliminate its inhibiting action and consequently initiate or stimulate the proliferation of supporting cells. By means of a maturation of at least part of the cells resulting from the division of the supporting cells, a regeneration of the sensory cells is brought about.

As is apparent from the statements up to now, according to the invention the inner ear disease or disorder involved is in particular a so-called perceptive deafness. This is linked with the already described damage or destruction of the hair sensory cells in the inner ear.

In the case of the active ingredient usable according to the invention, which inhibits or eliminates the inhibiting action of the cell cycle inhibitor, is preferably a substance, which normally acts in intracellular manner either directly or indirectly on the inhibitor, i.e. normally a peptide or protein. The active ingredient is preferably present in the form of a peptide or protein, which effects a peptide-peptide or protein-protein interaction with

TORNER MENTER CONTROL

This would then be the case of a "direct" influencing of the the inhibitor.

This would then be the case of a "direct" influencing of t is constituted by a ingredient is constituted peptides/

This would fi the active ingredient is constituted peptides/

the inhibitor. Codes one of the aforementioned peptides/

function of the inhibitor. function of the inhibitor. If the active ingredient is constituted by the aforementioned peptides for the amino acid sequence, it is possible to refer to an inucleic acid molecule, which sequence, it is possible to refer to an inucleic acid molecule, acid sequence, it is possible to refer to an inucleic acid molecule, acid sequence, it is possible to refer to an inucleic acid molecule, acid sequence, it is possible to refer to an inucleic acid molecule, acid sequence, it is possible to refer to an inucleic acid molecule, acid sequence, it is possible to refer to an increase the amino acid sequence. proteins for the amino acid sequence, it is possible to refer to an it is possible to refer to an nucleic acid molecule is possible to refer to an nucleic acid molecule is possible to refer to an nucleic acid molecule is possible to refer to an nucleic acid molecule is possible to refer to an nucleic acid molecule is possible to refer to an nucleic acid molecule is possible to refer to an nucleic acid molecule is possible to refer to an nucleic acid molecule is possible to refer to an nucleic acid molecule is possible to refer to an nucleic acid molecule is possible to refer to an nucleic acid molecule is possible to refer to an nucleic acid molecule is possible to refer to an nucleic acid molecule is possible to refer to an nucleic acid molecule is possible to refer to an nucleic acid molecule is possible to refer to an nucleic acid molecule is possible to refer to acid molecule is possible to refer to acid molecule is possible to refer to acid molecule in the coding nucleic acid molecule in the coding nucleic acid molecule in the possible to refer to acid molecule in the coding nucleic acid nucleic acid molecule, which codes one of the aforementioned peptides to an acid sequence, it is possible nucleic acid molecule, acid sequence, it is possible nucleic acid molecule, acid sequence, initially the coding nucleic proteins for the amino because initially the coding nucleic influencing, because initially the coding nucleic acid molecule. "indirect" influencing, because initially the coding nucleic acid molecule is said

"indirect" influencing, because cell and subsequently expressed.

"introduced into the corresponding active ingredient) is expressed.

introduced (serving directly as the active ingredient) introduced into the corresponding cell and subsequently the peptide/f arid introduced into the corresponding cell and subsequently is expressed. The active ingredient in active in active ingredient in active in molecule (serving directly as the active ingredient) is expressed.

The active ingredient is expressed. nucleic acid molecule can in particular be a recombined nucleic acid molecule, a molecule can fundamentally be a DNA molecule.

The nucleic acid molecule can fundamentally be a DNA molecule.

CDNA molecule or a RNA molecule. the inhibitor. Another active ingredient usable in preferred manner according to the so-call invention is a nucleic acid molecule, where use is made of the so-call invention is a nucleic acid molecule. Another active ingredient usable in preferred manner according to the ext in preferred manner according to the so-called where use is made of the so-called where use is made of the ext where use is made of the so-called where use is made of the ext. invention is a nucleic acid molecule, where use is made of the so-called where use is made of the so-called where use is made of the expert in this method which is fundamentally to the RNA of the which is complimentary to the RNA of the antisense method.

In this method which is complimentary to the RNA, which is complimentary to the RNA. antisense method.

In this method which is fundamentally known to the expense method.

In this method which is complimentary to the RNA antisense method.

This complimentary RNA is called antisense the complex RNA is called antisense the co use is normally made of a RNA. This complimentary RNA is called antisense RNA.

This complimentary RNA is called antisense RNA.

This complimentary RNA is called antisense RNA.

This complimentary RNA is called antisense RNA.

This synthesis of the protein product belonging and cDNA molecule or a RNA molecule. normal (physiological) gene. This complimentary RNA is called antisense-RNA.

This complimentary RNA is called antisense-RNA acid

The antisense-RNA can prevent the invention this means that a nucleic acid

The antisense-RNA case of the invention this means that a nucleic acid

to the gene. to the gene. In the case of the invention this means that a nucleic acid whose transcription itself or DNA, the organism or cell for the invention this means that a nucleic acid whose transcription this means that a nucleic acid that a nucleic ac molecule, e.g. the antisense-RNA itself or DNA, during whose transcription for into the antisense-RNA is formed, is introduced into of the cell cycle inhibiting action of the cell cycle inhibiting the inhibiting action of the cell cycle inhibiting the inhibiting action of the cell cycle inhibiting the inhibiting action of the cell cycle inhibiting action of the cell cycle inhibiting the inhibiting action of the cell cycle inhibiting action of the cell cycle inhibiting the inhibiting action of the cell cycle inhibiting action of the cell cycle inhibiting the inhibiting action of the cell cycle inhibiting action of the cell cycle inhibiting the inhibiting action of the cell cycle inhibiting action of the cycle inhibiti the antisense-RNA is formed, is introduced into the call cycle inhibiting action of the aid of lipid compounds, takes place with the aid of lipid compounds takes place with the aid of lipid compounds. inhibiting or eliminating the inhibiting action of the cell cycle inhibitor action of the cell cycle inhibitor of the cell cycle inhibitor of the cell cycle inhibitor of the cell cycle inhibiting action of the cell cycle inhibitor of the cycle i This introduction preferably takes place with the aid of lipid compounds, of the better docking and penetration of the better docking and penetrat As stated, the active ingredient in preferably a peptide-peptide or protein. As interaction, preferably a peptide-peptide or protein. As stated, the active ingredient in the case of the invention can effect a intercontain the case of the invention can intercontain in the case of the invention protein intercontain the active ingredient can be active ingredient. However, the active ingredient can be active indredient can be active indredient. However, the active ingredient can be active indredient can be active indredient. However, the active ingredient can be active indredient can be active indredient. However, the active indredient can be active indredient can be active indredient. However, the active indredient can be active indredient can be active indredient. direct interaction, preferably a peptide peptide or protein ingredient can nowever, however, action of the cell cycle inhibitor. the inhibiting action of the cell cycle action with the cell cycle eliminate the inhibiting action indirectly inhibit or eliminate the inhibiting action with the cell cycle action indirectly inhibit or eliminate the inhibiting action indirectly inhibiting action in acti action with the cell cycle inhibit or eliminate the inhibit or preferably better with a least as well or preferably inhibit interacts at least as inhibitor, in that it interacts at least as well or preferably heat least as we the nucleic acid molecule into the cell. also indirectly inhibit or eliminate the cell cycle inhibitor than the cell cycle inhibitor, in interaction partner of the cell cycle inhibitor, interaction partner of the cell cycle inhibitor. inhibitor, in that it interacts at least as well or preferably better with a evolving inhibitor than the cell cycle inhibitor from evolving that it interacts at least as well or preferably better than the cell cycle inhibitor from evolving the cell cycle inhibitor from evolving the cell cycle inhibitor from evolving the cell cycle inhibitor itself. This prevents the cell cycle inhibitor itself. physiological interaction partner of the cell cycle inhibitor from evolving this prevents the cell cycle inhibitor from evolving this prevents inhibitor itself.

cycle inhibitor itself. (inhibiting) action. Thus, e.g. in the case of the cyclin-dependent together with the cyclin-dependent known that it forms a Thus, e.g. in the case of the cyclin-dependent together with the cyclin approximate points at which peotide of the cyclin-dependent together with the cyclin peotide per together which peotide per together together at which peotide per the cyclin approximate the cyclin approx known that it forms a protein complex together with the cyclin-dependent rhus, e.g.

There are specific points at which peptide-peptide are specific points at which and the CDK2 or cyclin A. Thus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

Thus, e.g.

Thus, e.g.

There are cDK2 or cyclin A. Thus, e.g.

Thus, e.g.

There are cDK2 or cyclin A. Thus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific points at which peptide rhus, e.g.

There are specific poi its physiological (inhibiting) action. interactions occur between the place of a bonding point of bonding points between taken place of a several less strong bonding points identification and cyclin A and several between place of a bonding points between the place of a bonding points between blace of a bonding points between blace of a bonding points between both and cyclin A and several less strong bonding points between black of the place of a bonding points between both and cyclin A and several less strong bonding points between black of the place of a bonding point of the place kinase CDK2 and cyclin A. There are specific points at which pep the p27% and the CDK2 of were high a honding noint of were high interactions occur taken made of a honding noint of were high interactions has taken made of a honding noint of were high identification has taken made of a honding noint of were high identification has taken made of a honding noint of were high identification has taken made of a honding noint of were high identification has taken made of a honding noint of were high identification has taken made of a honding noint of were high identification has taken made of a honding noint of were high identification has taken made of a honding noint of were high identification has taken made of the control of the cont identification has taken place of a bonding point of very high affinity bonding point of very high affinity bonding point of very high affinity between bonding point of very high affinity between place of a bonding point of very high appropriate bonding point of very high affinity between place of a bonding point of very high affinity affinity affinity of very high affinity between p27kip and cyclin A and several less strong bonding points both bonding one of the bonding one extracting one of the bonding one extracting one of the bonding one extracting one extracting one of the bonding points where is no high or very high affinity bonding points where is no high or very high affinity bonding points between P27KLP, and Cyclin A or p27KLP, and the form of a further peptide/protein can be points where is no high in the form of a further peptide/protein can be points where ingredient, preferably in the form of a further peptide/protein can be points where there is no high in the form of a further peptide/protein can be points where there is no high in the form of a further peptide/protein can be preferably in the form of a further peptide/protein can be preferably in the form of a further peptide/protein can be preferably in the form of a further peptide/protein can be preferably in the form of a further peptide/protein can be preferably in the form of a further peptide/protein can be preferably in the form of a further peptide/protein can be preferably in the form of a further peptide/protein can be preferably in the form of a further peptide/protein can be preferably in the form of a further peptide/protein can be preferably in the form of a further peptide/protein can be preferably in the form of a further peptide/protein can be preferably in the form of a further peptide/protein can be preferably in the form of a further peptide/protein can be preferably in the form of a further peptide/protein can be preferably in the further peptide/protein c points where there is no high or very high affinity bonding/interaction, an high or very high affinity bonding/interaction of at least as high or preferably in the form of a further peptide/protein of at least as high or very high affinity bonding of at least as high or very high affinity bonding of at least as high or a form of a further peptide of at least as high or very high affinity bonding of at least as high or very high affinity bonding of at least as high or very high affinity bonding/interaction, an because of the protection of at least as high or very high affinity bonding/interaction of at least as high or very high affinity bonding high affinity bonding high and high affinity bonding high affinit active ingredient, preferably in the form of a further peptide/protein can be a further peptide/protein can be form of a further peptide/protein can be night or a bonding/interaction of at Least as high or active ingredient, preferably in the form of a further peptide/protein can be form of a further peptide/protein can be active ingredient, preferably in the form of a further peptide/protein can be active ingredient, preferably in the form of a further peptide/protein can be active ingredient, preferably in the form of a further peptide/protein can be active ingredient, preferably in the form of a further peptide/protein can be active ingredient. The second secon

The state of the state of

Preferably higher affinity with one of the two interaction partners at the standard physion prevents the standard physion physion prevents the standard physion particular bonding point.

This inhibits or prevents the standard physiothe physiothe corresponding bonding point for the physiothe Thus, e.g. for a bonding point between plantaged amino acid sequence can be developed optimized pentide structure or optimized pentide Thus, e.g. for a bonding point between p27kip, and cyclin A, but also developed with a structure or optimized amino point, which then bonds with a optimized peptide structure of p27kip, at this point, which then bonds with a for the amino acid sequence of p27kip, at this point, which then bonds with a structure of p27kip, at this point, which then bonds with a specific the amino acid sequence of p27kip, at this point, which then bonds with a sequence of p27kip, and cyclin A, but also con be developed and cyclin A, but also optimized pertide structure or optimized amino point, which then bonds with a cid sequence of cyclin A or sequence of parkip, at this point, sequence of cyclin A or the amino acid sequence of parkip, the corresponding sequence of cyclin A or higher affinity with the corresponding sequence of better, i.e. for the amino acid sequence of p27kip) at this point, which then bonds with a point, which then bonds are preferably and preferably with the corresponding sequence of p27kip) at this point, which then bonds are preferably and preferably with the corresponding structure e.g. and preferably better, i.e. higher such as optimized peptide structure e.g. and preferably better in the point of the preferably are point. Logical interaction partner is blocked. particular bonding point. better, i.e. higher such an optimized peptide structure introduced into the corresponding then be directly introduced into the corresponding then be directly introduced into the corresponding sequence of cyclin A or the e.g. and preferably introduced into the introduced into the corresponding sequence of cyclin A or the cyclin Cy CDK2 at this point. Such an optimized peptide structure e.g. and preferably introduced into the amino acids and can manner by an artificially comprises up to 15 amino acids in intracellular manner by acids comprises preferably expressed in intracellular manner by an artificially comprises up to 15 amino acids in intracellular manner by an artificially comprises up to 15 amino acids in intracellular manner by an artificially comprises up to 15 amino acids in intracellular manner by an artificially comprises up to 15 amino acids in intracellular manner by an artificially comprises up to 15 amino acids and can intracellular manner by an artificially comprises up to 15 amino acids in intracellular manner by an artificially comprises up to 15 amino acids in intracellular manner by an artificially comprises up to 15 amino acids in intracellular manner by an artificially comprises up to 15 amino acids in intracellular manner by an artificially comprises up to 15 amino acids in intracellular manner by an artificially comprises up to 15 amino acids in intracellular manner by an artificially comprises up to 15 amino acids in intracellular manner by an artificially comprises up to 15 amino acids in intracellular manner by an artificial by a comprise acids a comprises up to 15 amino acids and can then be directly introduced into to the interest of preferably and affinity of such a peptide the interest of preferably and the high affinity of such a peptide the interest of preferably and the high affinity of such a peptide the interest of preferably and the high affinity of such a peptide the interest of preferably and the high affinity of such a peptide the interest of the high affinity of such a peptide the interest of the high affinity of such a peptide the interest of the high affinity of such a peptide the interest of the high affinity of such a peptide the interest of the high affinity of such a peptide the interest of the high affinity of such a peptide the interest of the high affinity of such a peptide the high affinity of y expressed in intracellular manner by an artificially of such a peptide the interaction of such a peptide the formation of manner by an artificially of such a peptide the formation of manner by an artificially of such a peptide the formation of such a peptide the formation of such a peptide the formation of such a peptide the interaction of such a peptide the interaction of such as a peptide the interaction of such a peptide the interaction of such a peptide the interaction of such as a period of such as a p introduced gene. Through the physiological pased on the inhibiting action of the physiological based on the physiological pased o of the physiological pased on the inhibiting action ensures an at les the peptide complex. Thus. the active incredient ensures in the peptide the pertials of the pertials of the pertials of the pertials of the pertials. the peptide complex, based on the active ingredient inhibiting action of the cell cycle inhibiting action of the inhibition of a complete elimination of the inhibition or a complete elimination of the inhibition or a complete elimination of the inhibition or a complete elimination of the cell cycle inhibitor is prevented. Thus, the active ingredient ensures an at least the active ingredient inhibiting action of the starting point of the partial inhibition.

As a result of this process starting point of the active ingredient ensures an at least the inhibiting action of the inhibiting active indicates a point of the starting point of the starting point of the starting point of the inhibitor.

As a result of this process starting point of the inhibitor.

As a result of the inhibitor. cell cycle inhibitor. As a result of this process starting point of the cell invention the corresponding amino acid sequence in the cell invention with the corresponding amino acid sequence. invention the concentration of the same level as the corresponding concentration of the pertide/protein with the same level has to be roughly of the same level has to be roughly of the same level has to be roughly the same level has to be roughly of the same level has to be roughly the same level has to be roughly of the same level has the same level has to be roughly the same level has t peptide/protein with the corresponding amino acid sequence in the cell only the same level as to be inhibited or eliminated.

Peptide/protein with the same level as to be inhibited or eliminated.

Whose action is to be inhibitor, whose action is cell cycle inhibitor, introduced gene. has to be roughly of the same level as the corresponding concentration whose action is to be inhibited or and roughly whose action are approximately 10 nM/l and roughly cell cycle inhibitor; of p2Txipl are approximately concentrations. cell cycle inhibitor, whose action is to be inhibited or eliminated.

whose action is to be inhibited or eliminated.

whose action is to be inhibited or eliminated.

to be inhibited or eliminated.

to he inhibited or eliminated.

to be inhibited or eliminated.

to he inhibited or eliminated.

concertably 10 nM/1 and roughly

whose action is to be inhibited or eliminated.

to no no not concertably 10 nM/1 and roughly

cell cycle inhibitor, whose action is to be inhibited or eliminated. concentrations, e.g. of p27kip, are approximately even very low concentrations, e.g. 10,000 molecules per cell, invention.

correspond to 1,000 to the performance of the invention. cell cycle inhibitor. trations can suffice for the performance of the invention. It is also the invention. It is also invention. It is sufficient to introduce only a single copy of a pNA, coding that important that important is sufficient to introduce only a single copy of a pNA. important that for achieving such a concentration using gene-therapeutic for each cell. Compared with other methods it is sufficient acid sequence, for each cell. correspond to 1,000 to 10,000 molecules per cell, even very the invention.

correspond to 1,000 to 10,000 molecules per the invention.

correspond to 1,000 to 10,000 molecules per the invention.

correspond to 1,000 to 10,000 molecules per cell, even very the invention. methods it is sufficient to introduce only a single copy of a DNA, coding for each cell.

The corresponding amino acid sequence, concentrations or a larger number of the corresponding to use much higher concentrations. the corresponding amino acid sequence, for each cell. Compared with other of higher concentrations or a larger number of higher advantage.

the corresponding amino use much higher advantage.

The corresponding amino acid sequence, concentrations or a larger number of a larger number of higher concentrations or a larger number of higher number of higher concentrations or a larger number of higher concentrations or a larger number of higher concentrations or a According to a further development the active ingredient is in the form of a sobe performed in such a way that the According to a further development the process according to the invention of a sothe process according to the form of a sothe process according to the form of the form of the active ingredient is in the form of the active be Performed in such a way that the active ingredient is in the form of the ingredient is ingredient in gradient ingredient is ingredient in gradient ingredient ingr DNA copies, this represents a decisive advantage. called vector or vehicle; said vector or vehicle carrying at least one of protein acid weather acid molecules. Preferably it is a nucleic of protein acid molecules. Sequence of a pentide of protein above-described nucleic acid molecules for the amino acid sequence of a pentide of protein above-described nucleic acid molecule. Which codes for the amino acid sequence of a pentide of protein above-described nucleic acid molecule. above described nucleic acid molecules. Preferably it is a nucleic acid rival sequence of a peptide or protein acid sequence of a peptide or protein acid sequence of a peptide or viral sequence of a peptide or protein acid sequence of a peptide or viral sequence or molecule, which codes for the amino said vectors can be conventional vectors use serving as the active ingredient. the expert.

molecule vectors, as are known to the expert. non-viral vectors, as are known to the expert. When using viruses. In the expert. When using viruses, so adeno-associated viruses, s can be made of retroviruses, it is known be introduced into a cell.

the case of non-viral a "bare" DNA can be that nere fundamentally a "bare" be the case of non-viral properties that nere fundamentally a "bare" be the case of non-viral properties that nere fundamentally a "bare" be the case of non-viral properties that nere fundamentally a "bare" be the case of non-viral properties that nere fundamentally a "bare" be the case of non-viral properties that nere fundamentally a "bare" be the case of non-viral properties that nere fundamentally a "bare" be the case of non-viral properties that nere fundamentally a "bare" be the case of non-viral properties that nere fundamentally a "bare" be the case of non-viral properties that nere fundamentally a "bare" be the case of non-viral properties that nere fundamentally a "bare" be the case of non-viral properties that nere fundamentally a "bare" be the case of non-viral properties that nere fundamentally a "bare" be the case of non-viral properties that nere fundamentally a "bare" be the case of non-viral properties that nere fundamentally a "bare" be the case of non-viral properties that nere fundamentally a "bare" be the case of non-viral properties that nere fundamentally a "bare" be the that here fundamentally a "bare" DNA can be introduced in so-called liposomes are packed in so-called liposomes and cell. The organism and cell.

that here fundamentally a cid molecules form into the organism and cell.

preferably such nucleic acid molecules form into the organism and cell. the case of non-virally a "bare" DNA can be packed in so-called lipos that here fundamentally a acid molecules are packed in so-called lipos serving as the active ingreatent to the expert. preferably such nucleic acid molecules form into the organism and cell.

preferably such nucleic acid molecules form into the organism and because the form into the organism and preferred. The form into the organism and cell. and the second of the second

viral vectors have certain disadvantages known to the expert. As a result of the above-described use possibilities of the invention, it is here frequently possible to operate without using viral vectors, because the effectiveness of the active ingredients used is very high and it is correspondingly possible to operate with low concentrations.

In the invention the active ingredient used is preferably employed in a therapeutically active quantity. In the conventional manner this can be matched to the subject undergoing treatment and inter alia use can be made of known pharmaceutical additives. According to a further development the active ingredient used and correspondingly also the process according to the invention can be provided for local application. This makes it possible to avoid possible disadvantages of a systemic application. The target location of the process according to the invention, namely the inner ear, is particularly suitable for local application. Thus, in the present case the active ingredient can be introduced into the so-called perilymphatic space of the inner ear of the mammal, particularly human. This is a small liquid space with a very slow exchange rate, which is accessible to therapeutic intervention from the middle ear, e.g. via the membrane of the circular window. This perilymphatic space has a volume of only approximately 20 microlitres and is also in direct contact with the cells of the corti-organ. This ensures a direct action of the active ingredient on the sensory epithelium with its hair cells and supporting cells.

The invention also relates to the actual active ingredient, whose use is described in detail in the above-described process. Reference is made to the content and wording of claims 22 to 27. This active ingredient is intended for the regeneration of the sensory cells of the inner ear, particularly the hair sensory cells of the inner ear and is able to at least partly inhibit or eliminate the inhibiting action of a so-called cell cycle inhibitor present in the inner ear. The cell cycle inhibitor is preferably a cyclin-dependent kinase inhibitor, particularly the cyclin-dependent kinase inhibitor p27Kip1. Reference is made to the statements hereinbefore concerning the specific, preferred characteristics of the active ingredient. As stated, it can be at least one peptide/protein or at least one nucleic acid molecule, the latter preferably being an antisense-DNA or antisense-RNA or preferably codes for a corresponding peptide/protein usable as the active ingredient. The nucleic acid molecule can be a DNA molecule, a cDNA molecule or a RNA molecule. In particular, the nucleic acid molecule is introduced with the aid of a suitable vector or vehicle into the organism or cell and these can be the described viral or non-viral vectors or nucleic acid molecules packed in liposomes/lipoplexes.

> e, temperatura est en de est est

The invention finally relates to a pharmaceutical composition or medicament, which contains at least one active ingredient able to inhibit or eliminate the action of a cell cycle inhibitor present in the inner ear, in an active quantity, as well as conventionally a pharmaceutically acceptable carrier or support. With respect to the active ingredient contained in the composition or medicament express reference is made to the statements hereinbefore and the content of claims 28 and 29.

The described and further features of the invention can be gathered from the following description of a preferred embodiment in conjunction with the subclaims, the example and the drawing. The individual features can be implemented individually or in the form of subcombinations.

Fig. 1 is an electron micrograph of a cell in nuclear division in the sensory epithelium of the corti-organ of a so-called  $p2^{7Kip1}$  knockout mouse.

## Example

For the test use was made of a so-called  $p27^{Kip1}$  knockout mouse  $(p27^{-/-})$ , a mouse lacking the gene for expressing the protein  $p27^{Kip1}$ . Thus, in such a mouse  $p27^{Kip1}$  cannot evolve per se its cell cycle-inhibiting action.

The corti-organ is removed from such a  $p27^{\text{Kip1}}$  knockout mouse on the seventh day after birth (postnatal day 7) and is prepared in the usual way for electron microscopic examination making it possible to see the sensory epithelium of the corti-organ.

The result of the electron microscopic examination is shown in fig. 1. This electronic micrograph shows that a cell in nuclear division (mitosis), i.e. a mitotic cell is located between two left-hand, upper or right-hand, lower, inner hair cells, whereof the black bordered nuclei are at the left-hand top (complete) and right-hand bottom (partial). Mitosis is clearly visible on the condensed chromatin, the dissolved nuclear membrane and the basal body. the inner hair cell top left and the basal body are given English-language captions in the drawing to facilitate understanding.

Fig. 1 clearly shows that the lack of the cell cycle inhibitor  $p27^{\text{Kip1}}$  leads to the possibility of a cell division of supporting cells located there in the sensory epithelium of the corti-organ of the mouse. Mention is also made of the fact that in the case of the cell division shown in fig. 1 it is not a single phenomenon within the sensory epithelium of the corti-organ, but instead a large number of the cells there undergo a cell division and therefore pass through the cell cycle. The phenomenon shown in fig. 1

The state of the s

amikacin.

enables the conclusion to be drawn that not only a cell division, but also following a cell division, which represents the decisive step in the hair cell regeneration process, there is also a differentiation or maturation to hair sensory cells and finally a functional recovery of the auditory function of the sensory organ. Thus, a regeneration of the sensory cells is possible. This conclusion is supported by the fact that in the case of the knockout mouse there is not a single mitosis, but instead such knockout mice have more hair cells than normal mice, in which the protein p27Kip1 is expressed. Thus, the mitosis of the supporting cells also results in matured sensory cells. The correctness of this conclusion is confirmed by the following results. In the case of heterozygous knockout mice the regeneration of hair cells was proved in that in the second week of living of the animals when they evolve the auditory function, the hair cells were destroyed by the systemic administration of amikacin. After a further two weeks without any injection the animals were killed and their cochlea examined. This revealed regenerated hair cells in the cochlea, which are marked or labelled by a proliferation marker or label (bromodesoxyuridine - BrdU) e.g. administered with the

Thus, not only in knockout mice where the gene for  $p27^{\text{Kip1}}$  was missing from the outset, but also by inhibiting or eliminating the  $p27^{\text{Kip1}}$  expressed in the normal organism, e.g. with the aid of a peptide interacting with  $p27^{\text{Kip1}}$  or one of its physiological partners, with the aid of the nucleic acid sequence coding for this peptide or with the aid of an antisense-DNA/antisense-RNA it is possible to bring about a regeneration of the sensory cells. This can also take place by an only partial elimination of the function of  $p27^{\text{Kip1}}$ , because in the case of heterozygous mice a gene dose-dependent effect is observed.

Committee Street Land Land